THIS PRESS RELEASE AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND NOT FOR PUBLIC RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION FOR IMMEDIATE RELEASE.
The transaction is entered into on the same terms, subject to current market conditions, as the
The proceeds from this private placement will be used to fund the development of Kiadis’ K-NK cell therapy programs, including the clinical development of K-NK002 as an adjunctive therapy for patients with blood cancer undergoing a hematopoietic stem cell transplant, the development of K-NK003 for the treatment of acute myeloid leukemia, and the research and development of the company’s K-NK platform for solid tumor indications. As of
Earlier LSP investment funds are long-term shareholders in Kiadis. Following receipt of LSP’s proposal yesterday, both the management board and the supervisory board of Kiadis have carefully reviewed this additional funding option, with advice of Allen & Overy. The boards unanimously resolved that this additional funding transaction is in the best interest of Kiadis and the sustainable success of its business and all of its stakeholders. Kiadis supervisory board members, Messrs.
Bird & Bird acted as legal advisor to the Company for this transaction.
About Kiadis Pharma’s K-NK-Cell Therapies
Kiadis Pharma’s K-NK platform is designed to deliver potent NK cells to help each patient, without the need for genetic engineering. Kiadis Pharma’s programs consist of off-the-shelf and haploidentical donor NK-cell therapy products for the treatment of liquid and solid tumors as adjunctive and stand-alone therapies.
The Company’s PM21 particle technology enables improved ex vivo expansion and activation of cytotoxic NK cells supporting multiple high-dose infusions. Kiadis Pharma’s proprietary off-the-shelf NK-cell platform is based on NK cells from unique universal donors and can make NK-cell therapy product rapidly and economically available for a broad patient population across a potentially wide range of indications.
About
Founded in 1997,
Kiadis Pharma Contacts:
Tel: +1 (617) 710-7305 m.cimino@kiadis.com | Mary Clark, Tel: +44 203 950 9144 Tel: +31 610 942 514 kiadis@optimumcomms.com |
This press release is released by the Company and contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 ("MAR"), encompassing information relating to the private placement, and is disclosed in accordance with the Company's obligations under Article 17 of MAR.
For the purposes of MAR and Article 2 of Commission Implementing Regulation (EU) 2016/1055, this press release is being made on behalf of the Company by
Forward Looking Statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis Pharma’s or, as appropriate, Kiadis Pharma’s officers’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of known and unknown risks, uncertainties and assumptions that could cause actual results, performance, achievements or events to differ materially from those expressed, anticipated or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, regulation, competition and technology, can cause actual events, performance, achievements or results to differ significantly from any anticipated or implied development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result,
General
This press release is for information purposes only and shall not constitute an offer to buy, sell, issue, or subscribe for, or the solicitation of an offer to buy, sell, issue, or subscribe for any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unauthorised or unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any failure to comply with these restrictions may constitute a violation of the securities law of any such jurisdiction.
The new shares and warrants issued, or to be issued, in connection with the private placement have not been and will not be registered under the
This press release has been issued by and is the sole responsibility of the Company. No representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by Oppenheimer (apart from the responsibilities or liabilities that may be imposed by the regulatory regime established thereunder) or by any of its affiliates or agents as to, or in relation to, the accuracy or completeness of this press release or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefor is expressly disclaimed.
Oppenheimer is acting as the sole placement agent for the Company and for no-one else in connection with the private placement, and Oppenheimer will not be responsible to anyone other than the Company for providing the protections afforded to its customers or for providing advice to any other person in relation to the Placing or any other matter referred to herein.
The distribution of this press release and the offering of the new shares and warrants in certain jurisdictions may be restricted by law. No action has been taken by the Company, Oppenheimer or any of their respective directors, officers, partners, agents, employees, affiliates and advisors that would permit an offering of such shares or possession or distribution of this press release or any other offering or publicity material relating to such shares in any jurisdiction where action for that purpose is required. Persons into whose possession this press release comes are required to inform themselves about, and to observe such restrictions.
The press release does not constitute a recommendation concerning any investor's options with respect to the private placement. The new shares and warrants to which this press release relates may be illiquid and / or subject to restrictions on their resale. Recipient of this press release should conduct their own investigation, evaluation and analysis of the business, data and property described in the press release. The pricing and value of securities can go down as well as up. Past performance is not a guide to future performance. The contents of this press release are not to be construed as financial, legal, business or tax advice. If you do not understand the contents of this press release you should consult an authorised financial adviser, legal adviser, business adviser or tax adviser for financial, legal, business or tax advice.
© OMX, source